Merck KGaA (OTCMKTS:MKKGY – Get Free Report) was the target of a large increase in short interest in June. As of June 15th, there was short interest totaling 293,910 shares, an increase of 220.8% from the May 31st total of 91,604 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 140,159 shares, the days-to-cover ratio is presently 2.1 days.
Wall Street Analyst Weigh In
A number of analysts have weighed in on MKKGY shares. Sanford C. Bernstein upgraded shares of Merck KGaA to a “hold” rating in a research report on Thursday, March 19th. Jefferies Financial Group assumed coverage on shares of Merck KGaA in a report on Tuesday, May 26th. They set a “hold” rating for the company. Five investment analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company has an average rating of “Hold”.
Read Our Latest Research Report on MKKGY
Merck KGaA Trading Down 0.8%
Merck KGaA (OTCMKTS:MKKGY – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.45 by $0.14. The business had revenue of $6.03 billion during the quarter, compared to analyst estimates of $5.93 billion. Merck KGaA had a net margin of 12.07% and a return on equity of 8.79%. Analysts predict that Merck KGaA will post 1.87 earnings per share for the current year.
Merck KGaA Company Profile
Merck KGaA, Darmstadt, Germany, commonly referred to as Merck Group, is a multinational science and technology company with origins dating back to 1668. The company develops and manufactures products and technologies across healthcare, life science and electronics applications. It is distinct from the U.S. pharmaceutical company Merck & Co; Merck KGaA is a European group headquartered in Darmstadt and is publicly listed in Germany with an OTC American depositary receipt available under the symbol MKKGY.
Merck’s Healthcare business develops prescription medicines and related services focused on areas such as oncology, immunology, neurology (including therapies for multiple sclerosis) and fertility.
Recommended Stories
- Five stocks we like better than Merck KGaA
- As Stablecoins Keep Growing, These 2 Stocks Benefit
- Apple Just Handed These 4 Memory Stocks Their Best News of the Year
- Costco’s Secret Growth Engine May Be Running Out of Gas
- Why Alphabet’s Pullback May Be an Opportunity in Disguise
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
